-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VeaL6zFmasDsa71tLB519bBgaGXsiI0Mt1crHsFPCEEjMm49Qz/pT607EoRCOEPJ trTAt90TJnlIqqJBuGvilA== 0001125282-05-005149.txt : 20051004 0001125282-05-005149.hdr.sgml : 20051004 20051004174936 ACCESSION NUMBER: 0001125282-05-005149 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20050930 FILED AS OF DATE: 20051004 DATE AS OF CHANGE: 20051004 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INKINE PHARMACEUTICAL CO INC CENTRAL INDEX KEY: 0000929547 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133754005 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1787 SENTRY PARKWAY WEST STREET 2: BUILDING 18 SUITE 440 CITY: BLUE BELL STATE: PA ZIP: 19422 BUSINESS PHONE: 2152836850 MAIL ADDRESS: STREET 1: 1787 SENTRY PARKWAY WEST STREET 2: BUILDING 18 SUITE 440 CITY: BLUE BELL STATE: PA ZIP: 19422 FORMER COMPANY: FORMER CONFORMED NAME: PANAX PHARMACEUTICAL CO LTD DATE OF NAME CHANGE: 19940906 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SCHELLENGER NORMAN D CENTRAL INDEX KEY: 0001206824 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-25572 FILM NUMBER: 051122922 BUSINESS ADDRESS: STREET 1: C/O INKINE PHARMACEUTLCAL CO INC STREET 2: 1787 SENTRY PARK WEST STE 440 CITY: BLUE BALL STATE: PA ZIP: 19422 BUSINESS PHONE: 2152836866 MAIL ADDRESS: STREET 1: INKINE PHARMACEUTICAL CO INC STREET 2: 1787 SENTRY PARK WEST STE 440 CITY: BLUE BALL STATE: PA ZIP: 19422 4 1 form.xml X0202 4 2005-09-30 1 0000929547 INKINE PHARMACEUTICAL CO INC INKP 0001206824 SCHELLENGER NORMAN D 1787 SENTRY PARKWAY WEST BUILDING 18 SUITE 440 BLUE BELL PA 19422 1 Common Stock (right to buy) 1.60 2005-09-30 4 D 0 25000 D 2012-11-10 Common Stock 25000 0 D Common Stock (right to buy) 2.82 2005-09-30 4 D 0 30500 D 2013-06-01 Common Stock 30500 0 D Common Stock (right to buy) 4.20 2005-09-30 4 D 0 21000 D 2014-06-06 Common Stock 21000 0 D Common Stock (right to buy) 3.92 2005-09-30 4 D 0 5000 D 2014-08-22 Common Stock 5000 0 D Common Stock (right to buy) 2.11 2005-09-30 4 D 0 51000 D 2015-06-07 Common Stock 51000 0 D All of the options described above were converted in the merger into options to purchase Salix common stock based on an exchange ratio of 0.1737. These options, which are fully vested, now represent the right to purchase 23,015 shares of Salix common stock at a weighted average exercise price of $14.89 per share. Robert F. Apple, as attorney-in-fact for Norman D. Schellenger 2005-10-04 -----END PRIVACY-ENHANCED MESSAGE-----